-$0.27 EPS Expected for NeuBase Therapeutics, Inc. (NASDAQ:NBSE) This Quarter

Equities research analysts predict that NeuBase Therapeutics, Inc. (NASDAQ:NBSEGet Rating) will post ($0.27) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for NeuBase Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.25). NeuBase Therapeutics posted earnings per share of ($0.29) in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.9%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that NeuBase Therapeutics will report full year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.15) to ($0.89). For the next financial year, analysts forecast that the business will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.31) to ($0.99). Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for NeuBase Therapeutics.

A number of brokerages recently issued reports on NBSE. Zacks Investment Research downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Chardan Capital lowered their price target on NeuBase Therapeutics from $18.00 to $9.00 in a research report on Friday, May 13th.

Institutional investors have recently bought and sold shares of the company. Morgan Stanley raised its stake in NeuBase Therapeutics by 393.9% in the second quarter. Morgan Stanley now owns 119,678 shares of the company’s stock valued at $574,000 after buying an additional 95,447 shares during the last quarter. Geode Capital Management LLC boosted its stake in NeuBase Therapeutics by 2.5% in the 3rd quarter. Geode Capital Management LLC now owns 239,819 shares of the company’s stock worth $865,000 after purchasing an additional 5,963 shares in the last quarter. Jacob Asset Management of New York LLC grew its position in NeuBase Therapeutics by 17.9% during the 3rd quarter. Jacob Asset Management of New York LLC now owns 407,500 shares of the company’s stock worth $1,471,000 after purchasing an additional 62,000 shares during the last quarter. Stonepine Capital Management LLC increased its stake in NeuBase Therapeutics by 253.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 109,742 shares of the company’s stock valued at $396,000 after purchasing an additional 78,672 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of NeuBase Therapeutics by 1.5% in the third quarter. GSA Capital Partners LLP now owns 351,178 shares of the company’s stock worth $1,268,000 after buying an additional 5,027 shares during the last quarter. 34.30% of the stock is owned by hedge funds and other institutional investors.

NBSE traded down $0.01 during mid-day trading on Friday, reaching $1.00. 200 shares of the company traded hands, compared to its average volume of 81,391. The stock has a market capitalization of $32.26 million, a P/E ratio of -0.96 and a beta of 0.79. The company’s fifty day moving average price is $1.49 and its 200-day moving average price is $2.06. NeuBase Therapeutics has a 52-week low of $0.89 and a 52-week high of $5.51.

NeuBase Therapeutics Company Profile (Get Rating)

NeuBase Therapeutics, Inc, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.

Recommended Stories

Get a free copy of the Zacks research report on NeuBase Therapeutics (NBSE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.